April 1 (Reuters) - Mira Pharmaceuticals Inc MIRA.O:
MIRA PHARMACEUTICALS INC - ENROLLS FIRST SUBJECTS IN PHASE 1 TRIAL FOR KETAMIR-2 - SEC FILING
MIRA PHARMACEUTICALS INC - PHASE 1 STUDY EXPECTED TO COMPLETE BY Q4 2025 - SEC FILING
MIRA PHARMACEUTICALS INC - FIRST HUMAN EFFICACY DATA EXPECTED IN H1 2026
Source text: [ID:n0001641172-25-001987]
Further company coverage: MIRA.O
(((( Reuters.briefs@thomsonreuters.com ;));))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.